Routine Chromosomal Microarray Analysis is Necessary in Korean Patients With Unexplained Developmental Delay/Mental Retardation/Autism Spectrum Disorder

Saeam Shin, M.D.¹, Nae Yu, M.D.¹, Jong Rak Choi, M.D.¹, Seri Jeong, M.D.², and Kyung-A Lee, M.D.¹
Department of Laboratory Medicine¹, Yonsei University College of Medicine, Seoul; Department of Laboratory Medicine², Kosin University College of Medicine, Busan, Korea

Background: All over the world, chromosomal microarray (CMA) is now the first tier diagnostic assay for genetic testing to evaluate developmental delay (DD), mental retardation (MR), and autism spectrum disorder (ASD) with unknown etiology. The average diagnostic yield of the CMA test is known to be about 12.2%, while that of conventional G-banding karyotype is below 3%. This study aimed to assess the usefulness of CMA for the purpose of clinical diagnostic testing in the Korean population.

Methods: We performed CMA and multiplex ligation-dependent probe amplification (MLPA) tests in 96 patients with normal karyotype and unexplained DD, MR, or ASD. The CMA was conducted with CytoScan 750K array (Affymetrix, USA) with an average resolution of 100 kb.

Results: Pathogenic copy number variations (CNVs) were detected in 15 patients by CMA and in two patients by MLPA for four known microdeletion syndromes (Prader-Willi/Angelman syndrome, DiGeorge syndrome, Miller-Dieker syndrome and Williams syndrome) designated by National Health Insurance system in Korea. The diagnostic yield was 15.6% and 2.1%, respectively. Thirteen (13.5%) patients (excluding cases with pathogenic CNVs) had variants of uncertain clinical significance. There was one patient with a 17.1-megabase (Mb) region of homozygosity on chromosome 4q.

Conclusions: Our findings suggest the necessity of CMA as a routine diagnostic test for unexplained DD, MR, and ASD in Korea.

Key Words: Copy number variation, Chromosomal microarray, Developmental delay, Mental retardation, Autism spectrum disorders

INTRODUCTION

Clinical genetic testing plays an important role in evaluating patients with developmental delay (DD), mental retardation (MR), and autism spectrum disorders (ASD) with unknown etiology. DD indicates deficits in learning and adaptive functioning at the expected age. MR, often referred to as “intellectual disability”, is a disorder with intellectual and adaptive deficits and can be diagnosed after the age of five years [1]. MR and DD affect 1-3% of general population [2]. ASD encompasses a group of disorders like autism, Asperger’s syndrome, and pervasive developmental disorder. ASD shows features like impairment in social communication and interactions, and repetitive and restrictive behaviors [1]. The frequency of occurrence of ASD is approximately 1% of general population [1]. Genetic causes, including known genetic syndromes and chromosomal abnormalities, comprise the main etiology of these disorders. Approximately 17.4-47.1% of DD/MR and 10% of ASD can be explained by
genetic causes [3, 4].

The National Health Insurance system of the Republic of Korea only permits multiplex ligation-dependent probe amplification (MLPA) tests for four microdeletion syndromes (Prader-Willi/Angelman syndrome, DiGeorge syndrome, Miller-Dieker syndrome, and Williams syndrome), conventional cytogenetics, and FISH. Thus, the medical institutions in Korea cannot perform other diagnostic genetic tests. Conventional cytogenetics allows for detection of numerical and structural chromosomal abnormalities present in the entire genome, but has a limited resolution of 5–10 megabases (Mb). Thus, submicroscopic aberrations cannot be detected, and interpretation of the test results remains subjective. FISH and MLPA can detect specific cytogenetic aberrations with a higher sensitivity than conventional cytogenetics; however, they cannot cover entire regions of chromosomes. Thus, it takes substantial effort to detect abnormalities involving multiple regions, and the diagnostic yield is decreased when the clinical spectrum of the disease is variable. DD, MR, and ASD are difficult to define disease categories clinically owing to overlapping symptoms and comorbidities.

Chromosomal microarray (CMA) is now recommended worldwide as the first-tier clinical diagnostic test for patients with DD, MR, and ASD of unknown causes [5]. CMA detects copy number variations (CNVs) in the entire genome with a much higher resolution than conventional cytogenetics. Before the CMA test was adopted as a routine clinical diagnostic test, conventional cytogenetics and single gene tests such as fragile-X syndrome testing were done as initial tests for unexplained DD, MR, and ASD. However, the diagnostic yields of conventional cytogenetics and fragile-X syndrome testing in patients with DD/MR is below 3% and 1.2%, respectively [5, 6]. CMA detects pathogenic CNVs with an average diagnostic yield of 12.2% in 33 previous studies involving 21,698 patients with neurodevelopmental disorders or multiple congenital anomalies [5].

We evaluated the utility of CMA as a routine clinical diagnostic test in the Korean population. In addition, we aimed to report a few interesting clinical cases confirmed by CMA test. We used Affymetrix single nucleotide polymorphism (SNP) array with an average resolution of 100 kb. The SNP array has been validated in a previous study indicating that it has sufficient resolution to detect single gene deletions [7]. Although CMA detects genomic imbalance with higher diagnostic yield than conventional cytogenetics, it cannot detect balanced rearrangements and low-level mosaicism [8]. Thus, we selected clinically affected individuals with normal karyotype.

METHODS

1. Patients

Genetic tests were requested by physicians from pediatrics, rehabilitation, neurology, and psychiatric departments for unexplained DD, MR, and ASD with or without dysmorphia or seizures. Written informed consent approved by institutional review board was obtained from patients or patients’ parents for genetic analysis.

Conventional G-banded karyotype analysis from peripheral blood was performed as a part of initial screening tests, and 96 patients with normal karyotypes were included in this study. As we retrospectively performed CMA using the blood samples collected during MLPA studies, parental samples could not be obtained and were therefore, not available for analysis.

From March 2012 to April 2014, 96 patients with normal karyotype (67 males and 29 females, Table 1) were referred for further genetic testing. The median age at diagnosis was three

| Sex       | Total No. (%) | CNVs (%) | With pathogenic CNVs (%) | With VOUS (%) | With benign CNVs (%) |
|-----------|---------------|----------|--------------------------|---------------|----------------------|
| Male      | 67 (69.8)     | 11 (16.4)| 8 (11.9)                 | 1 (1.5)       |                      |
| Female    | 29 (30.2)     | 4 (13.8) | 5 (17.2)                 | 4 (13.8)      |                      |

| Clinical features | Total No. (%) | CNVs (%) | With pathogenic CNVs (%) | With VOUS (%) | With benign CNVs (%) |
|-------------------|---------------|----------|--------------------------|---------------|----------------------|
| ASD               | 34 (35.4)     | 0 -      | 2 (5.9)                  | 2 (5.9)       |                      |
| DD/MR             | 54 (56.3)     | 15 (27.8)| 7 (13)                   | 3 (5.6)       |                      |
| ASD and DD/MR     | 8 (8.3)       | 0 -      | 4 (50)                   | 0 -           |                      |
| Total             | 96 (100)      | 15 (15.6)| 13 (13.5)                | 5 (5.2)       |                      |

*Patients with pathogenic CNVs were excluded; †Patients with pathogenic CNVs or with VOUS were excluded.

Abbreviations: CNV, copy number variation; VOUS, variant of uncertain clinical significance; ASD, autism spectrum disorder; DD, developmental delay; MR, mental retardation.

http://dx.doi.org/10.3343/alm.2015.35.5.510
years (range: 7 months-22 yr). Thirty four patients were ASD, 54 patients were DD and/or MR, and 8 patients were ASD combined with DD and/or MR (Table 1).

2. DNA preparation
EDTA whole blood was used to extract DNA by using the Easy-DNA kit (Invitrogen Corporation, Carlsbad, CA, USA). The concentration and quality of genomic DNA was analyzed by Nanodrop ND-1000 (Thermo Scientific, Wilmington, DE, USA).

3. MLPA
Microdeletion syndromes were screened by using SALSA MLPA P245 Microdeletion Syndromes probemix (MRC-Holland, Amsterdam, The Netherlands) according to the manufacturer’s instructions. The P245 probemix contains 49 different MLPA probes with amplification product sizes between 130 and 486 nucleotides. The probes target 40 causative genes implicated in 23 known microdeletion/microduplication syndromes. DNA was denatured at 98°C for five minutes and hybridized with the probe set overnight at 60°C. Ligation reaction with ligase-65 enzyme was performed at 54°C for 15 min, followed by five minutes at 98°C for heat inactivation of the enzyme. PCR was performed with the specific SALSA PCR primers for 35 cycles (95°C for 30 sec; 60°C for 30 sec; 72°C for one minute) by using the GeneAmp PCR System (Applied Biosystems, Foster City, CA, USA). MLPA fragment analysis data were generated by using the Applied Biosystems 3,500×L Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). The data were analyzed by using the GeneMarker software (SoftGenetics, State College, PA, USA). For confirmatory analysis of abnormal results found with the P245 screening probemix, an MLPA test with P372, P373, or P374 syndrome-specific probemix, or a P339 SHANK3 probemix (MRC-Holland) was performed by using the same protocol. Pathogenic CNVs detected by CMA that were smaller than 1 Mb were confirmed by using a P343 or P181 probemix.

4. Chromosomal microarray
CMA was performed with a CytoScan 750K array (Affymetrix, Santa Clara, CA, USA) according to the manufacturer’s recommendations. The platform is composed of 550,000 non-polymorphic CNV probes and more than 200,000 SNP probes with an average resolution of 100 kb. The data were analyzed by using Chromosome Analysis Suite v2.1 Software (Affymetrix) and Nexus Copy Number v.7.5 Software (BioDiscovery, El Segundo, CA, USA). The February 2009 human reference sequence (GRCh37/Hg19) was used for genomic assembly.

5. Interpretation of detected CNVs
Detected CNVs were classified as pathogenic, benign, or variant of uncertain clinical significance (VOUS) in accordance with the recommended guidelines from the International Standard Cytogenomic Array and the American College of Medical Genetics [5, 9, 10]. The data were interpreted by using information available in scientific literature, public databases and other general information about pathogenic or benign CNVs (size, content of Online Mendelian Inheritance in Man [OMIM] morbid genes or dosage sensitive genes, and type of dosage imbalance: duplication or deletion) [5, 11]. Genomic map from the UCSC Genome Browser (http://genome.ucsc.edu/cgi-bin/hgGateway) was used to map the locations of CNVs and gene distribution. The Database of Genomic Variants (DGV, http://dgv.tcag.ca/dgv/app/home) provided catalogs of structural variations found in healthy controls. The dbVar (http://www.ncbi.nlm.nih.gov/dbvar/) database was also used to get information about CNVs from both normal and diseased populations. We also used the Database of Chromosomal Imbalance and Phenotype in Humans using Ensembl Resources (DECIPHER, https://decipher.sanger.ac.uk/) as a reference for known microdeletion and microduplication syndromes, and the OMIM (http://omim.org/) for disease-causing genes, their functions and inheritance patterns.

Besides excluding pathogenic CNVs overlapping with known genomic imbalance syndromes and benign CNVs reported as normal variant in healthy controls, VOUS should meet at least one of the three criteria: the CNV is not a common polymorphism, OMIM genes in the CNV interval are not known for dosage sensitivity, and are not associated with patient’s phenotypes.

RESULTS
1. Results of MLPA and CMA
We identified 42 CNVs in 33/96 (34.4%) patients. Among these, 17 CNVs were classified as pathogenic (40.5%), 15 as VOUS (35.7%), and 10 as benign (23.8%). One or more pathogenic CNVs were reported in 15 patients (Table 1). Therefore the diagnostic yield of CMA was 15.6% (15/96) in our study. VOUS, excluding cases with pathogenic CNVs, were reported in 13/96 patients (13.5%). One or more benign CNVs, excluding cases with pathogenic CNVs and VOUS, were reported in five patients (5.2%).

Most of the 15 CNVs of unknown significance were not a common polymorphism, except a 2.3 kb-sized duplication at 8p23.2 found in three patients (Table 2, Case 20, 21, and 22). The duplicated region, which includes CSMD1 (MIM 608397) gene,
### Table 2. Summary of clinical features and genetic test results of patients with copy number variants or loss of heterozygosity

| Case | Age (yr) | Sex | Clinical features | MLPA | Microarray | Size (kb) | OMIM genes (N) | Critical genes or region | Classification | Known microdeletion syndrome | Reasons of classification* |
|------|----------|-----|-------------------|------|------------|-----------|---------------|------------------------|---------------|-----------------------------|--------------------------|
| 1    | 1        | M   | DD, seizure, both pes planovalgus, cleft palate, simian crease on left hand, cryptorchidism on right | 15q11.2 (P181)x1 | 1q21.1 (145,512,555-145,888,926)x1/1q44 (244,933,278-247,517,799)x1/15q11.2 (22,770,421-23,277,436)x1 | 376/2,584/507 | 8/9/4 | -/1q44/15q11.2 | Benign/Pathogenic/Pathogenic | -/MIM 612337/MIM 615656 | 2/1/1 |
| 2    | 5        | M   | DD, seizure, short stature, microcephaly | Negative | 3q27.3q29 (186,874,563-194,994,915)x1 | 8,120 | 27 | 3q27.3 | Pathogenic | 3q27.3 deletion syndrome [36] | 1 |
| 3    | 3        | F   | DD, microcephaly, bulbous nose, low set ears, clinodactyly of the hands, pes planovalgus | 10p14-15 (P245,P372)x3 | 4q35.1q35.2 (185,230,774-190,837,600)x1/10p15.3p11.23 (96,852-28,456,830)x3 | 5,606/28,360 | 16/92 | CASP3, PDLM3, KLKB1, F11, FAT1/GATA3 | Pathogenic/Pathogenic | 4q deletion syndrome [18]/MIM 146255 | 1 |
| 4    | 3        | M   | DD, esotropia on left eye | 5p15 (P245)x1 | 5p15.33p15.31 (113,576-7,183,668)x1 | 7,070 | 27 | TERT | Pathogenic | Cri du chat syndrome | 1 |
| 5    | 6        | F   | DD | Negative | 8p23.1 (8,107,752-7,183,668)x1 | 3,775 | 17 | GATA4 | Pathogenic | 8p23.1 deletion syndrome [37, 38] | 1 |
| 6    | 2        | M   | DD | Negative | 8p23.3p23.1 (158,048-6,590,060)x3/10q26.13q26.3 (124,682,180-135,426,836)x1 | 6,432/10,744 | 8/40 | -/DOCK1 | Pathogenic/VOUS | -/MIM 609625 | 4, 5, 6/1 |
| 7    | 2        | M   | DD, torticollis, pes planovalgus, right deafness, downsizing palpebral fissures | 22q13.33 (P245,P373)x1 | 9p24.3p22.3 (124,682,180-135,426,836)x1/10q26.13q26.3 (124,682,180-135,426,836)x1 | 15,891/4,407 | 40/31 | -ARS3, SHANK3, ACR | Pathogenic/VOUS | -/Phelan-McDermid syndrome | 4, 5/1 |
| 8    | 3        | F   | DD | Negative | 10p15.3 (100,047-2,969,599)x1 | 2,869 | 6 | ZMYND11 | Pathogenic | 10p15.3 deletion syndrome [39] | 1 |
| 9    | 1        | M   | DD, lipomegongomyelocele | Negative | 10q26.2q26.3 (130,158,704-135,426,836)x1 | 5,267 | 20 | TERT | Pathogenic | MIM 609625 | 1 |
| 10   | 4        | M   | DD, seizure | 15q11.2 (P181)x3 | 15q11.2 (22,770,421-23,625,785)x2 | 15q11.2 | 855 | 4 | 15q11.2 | Pathogenic | MIM 608636 | 1 |
| 11   | 1        | F   | DD, seizure | Negative | 15q11.2 (P245,P374)x1 | 5,267 | 20 | 10q26 | Pathogenic | SNRPN, UBE3A | MIM 608636 | 1 |
| 12   | 7        | M   | MR | 15q13.3 (P343)x3 | 15q13.3 (31,999,631-32,444,043)x3 | 444 | 1 | CHRNA7 | Pathogenic | MIM 608636 | 1 |
| 13   | 2        | M   | DD, abnormality of the skin, pectus carinatum | Negative | 16p13.11 (15,450,289-16,497,406)x3 | 1,047 | 8 | 16p13.11 | Pathogenic | 16p13.11 duplication syndrome [40] | 1 |
| 14   | 7        | M   | MR, full cheek, bulbous nose, low set ears, narrow forehead | 22q11 (P245,P372)x1 | 16p11.2 (32,524,764-33,863,672)x3/22q11.21 (18,916,842-21,800,471)x1 | 1,338/2,883 | -/39 | -/TBX1, CRKL | Pathogenic/Pathogenic | -/DiGeorge syndrome | 2, 3/1 |

(Continued to the next page)
| Case | Age (yr) | Sex | Clinical features | MLPA | Microarray | Size (kb) | OMIM genes (N) | Critical genes or region | Classification | Known microdeletion syndrome | Reasons of classification* |
|------|----------|-----|-------------------|------|------------|-----------|---------------|------------------------|---------------|----------------------------|-------------------------|
| 15   | 2        | M   | DD                | 2q13.33 | 22q13.31q13.33(48,398,495–51,154,658)x1 | 2,756 | 27 | ARSA, SHANK3 | Pathogenic | Phelan-McDermid syndrome | 1 |
| 16   | 5        | M   | MR, ASD           | Negative | 1q42.12(225,168,456–225,520,146)x1 | 351 | 1 | - | VOUS | 4, 5, 6 |
| 17   | 1        | M   | DD, seizure       | 2q11.1(P181)x3 | 2q11.1(95,518,497–96,326,105)x3 | 808 | 4 | - | VOUS | 4, 5, 6 |
| 18   | 12       | F   | MR                | Negative | 2q13(110,498,141–110,980,295)x1 | 482 | 4 | - | VOUS | 4, 6 |
| 19   | 5        | M   | ASD, DD, MR       | Negative | 6q22.31(121,220,756–121,617,795)x1 | 397 | 1 | - | VOUS | 4, 5 |
| 20   | 8        | M   | DD, MR, pes planovalgus | Negative | 8p23.2(3,685,300–5,935,671)x3 | 2,250 | 1 | - | VOUS | 5 |
| 21   | 4        | F   | DD, ASD           | Negative | 8p23.2(3,685,300–5,935,671)x3 | 2,250 | 1 | - | VOUS | 5 |
| 22   | 1        | M   | DD                | Negative | 8p23.2(3,685,300–5,935,671)x3 | 2,250 | 1 | - | VOUS | 5 |
| 23   | 3        | M   | DD, MR            | Negative | 11q13.4(70,993,028–71,745,766)x3 | 753 | 6 | - | VOUS | 4, 5 |
| 24   | 2        | F   | DD, alternating exotropia, vesicoureteral reflux | Negative | 11q21(95,576,015–96,054,843)x3 | 479 | 2 | - | VOUS | 4, 5, 6 |
| 25   | 10       | M   | ASD               | Negative | 12p11.23(27,283,451–27,793,637)x3 | 510 | 3 | - | VOUS | 4, 5, 6 |
| 26   | 3        | M   | ASD, DD, MR       | Negative | 14q12(25,529,986–26,282,808)x3 | 753 | - | - | VOUS | 3, 4 |
| 27   | 7        | F   | MR                | Negative | 16p11.2(31,991,160–33,981,750)x3/ Xp21.1p14(37,046,232–37,682,073)x3 | 1,990/635 | -3 | -/ | Benign/VOUS | 2, 3/4, 5, 6 |
| 28   | 12       | F   | ASD               | Negative | 19p13.2(940,905–3,957,892)x1 | 1,016 | 23 | - | VOUS | 4, 5, 6 |
| 29   | 9m       | F   | DD, hearing impairment, central hypotonia | Negative | 4q32.1q34.1(158,700,137–175,792,268)x2| 17,092 | 28 | - |  |

*1. Overlapping with a known genomic imbalance syndrome; 2. In the category of genomic imbalance in healthy individuals as per public database; 3. No OMIM genes in the CNV interval; 4. CNV is not a common polymorphism; 5. OMIM genes in the CNV interval are not known for dosage sensitivity; 6. OMIM genes in the CNV interval are not associated with patient’s phenotype.

Abbreviations: MLPA, multiplex ligation-dependent probe amplification; VOUS, variant of uncertain clinical significance; ASD, autism spectrum disorder; DD, developmental delay; MR, mental retardation; m, months.
was also found in normal controls [12]. CSMD1 was shown to be interrupted by duplication in a patient with speech delay and autism in a previous study [13].

One patient showed a deletion in 2q13 (Case 18), which included four OMIM genes (RGPD6, RGPD5, MALL, and NPHP1). The four genes are not known to have any relation with this patient's phenotype, but homozygous deletion of NPHP1 (MIM 607100) is known to be associated with nephronophthisis [14]. TBC1D32 gene (MIM 615867) was deleted in one patient (Case 19). TBC1D32 has been reported to be mutated in a patient with multiple congenital anomalies [15]. A duplication at 11q13.4 in a patient (Case 23) includes six OMIM genes (DHCR7, NADSYN1, KRTAP5-9, FAM86C1, IL18BP, and NUMA1). Mutation of DHCR7 gene is associated with Smith-Lemli-Opitz syndrome (SLOS, MIM 270400), which is an autosomal recessive multiple congenital anomaly and intellectual disability syndrome [16]. Thus far, the only reported DHCR7 mutations associated with SLOS are point mutations or multiple exonic deletions [16,17]. Thus, it is difficult to interpret the significance of duplication in our patient. A 753 kb-sized duplication at 14q12 in a patient (Case 26) contains no OMIM gene, so the CNV is likely to have a benign nature. However, we interpreted it as VOUS because the duplicated region was not reported in databases for control population [9].

Pathogenic CNVs were identified in 27.8% patients with DD and/or MR (Table 1). No pathogenic CNVs were seen in patients with ASD and ASD combined with DD and/or MR in our study. The size range of the pathogenic CNVs was 444 kb to 28.4 Mb. Most of the pathogenic CNVs (94.1%) were above 500 kb (Table 3). Six CNVs between 5-10 Mb and three CNVs above 10 Mb were not detected by conventional cytogenetics. All benign CNVs were below 5 Mb (Table 3).

MLPA microdeletion syndrome screening probemix for 23 chromosomal disorders detected six patients with known microdeletion or microduplication syndromes with a diagnostic yield of 6.3%. There were one patient with Angelman syndrome and one with DiGeorge syndrome. Therefore, the diagnostic yield of four microdeletion syndromes designated by National Health Insurance system in Korea was 2.1%.

2. Clinical case reports

1) Hypoparathyroidism, sensorineural deafness, and renal dysplasia syndrome

A 3-yr-old female (Table 2, Case 3) was referred for evaluation of developmental delay. G-banded karyotype was normal, while CMA revealed a 5.6 Mb deletion at 4q35.1q35.2 region and a 28.4 Mb duplication at 10p15.3p11.2 region.

Chromosome 4q deletion is known to be associated with intellectual disability, ASD, and craniofacial dysmorphism [18]. The critical region for ASD phenotype, containing MTNR1A, FAT1, and F11 at 4q35.2 [18], is identical to that in our patient. Duplication of GATA3 gene at 10p14 can cause hypoparathyroidism, sensorineural deafness, and renal dysplasia syndrome (HDR syndrome, MIM 146255) [19]. DD and facial dysmorphism have also been described in a HDR syndrome patient [19]. A previous study reported unbalanced cryptic translocation der(4)(4;10)(q35;p15), similar to our case [20]. Parental study revealed that the genomic imbalance was originated from unbalanced segregation of maternal balanced reciprocal translocation t(4;10)(q35;p15) [20]. Both patients showed learning disabilities, facial dysmorphism, and immunodeficiency [20]. Our patient's karyotype was initially interpreted as normal, however, after CMA results, a more detailed karyotype analysis revealed der(4)(4;10)(q35;p15), as previously described [20].

There were three patients with cryptic unbalanced translocations involving two chromosomes in our study (Case 3, 6, and 7), suggesting inheritance from parental balanced translocation. In these cases, other family members were given genetic evaluation and proper counseling about the disorders and the recurrence risk in family [9].

2) Patient with a region of homozygosity on chromosome 4

A 9-month-old female (Table 2, Case 29) was evaluated for delayed development due to central hypotonia. CMA showed no CNV, but there was one 17.1-Mb region of homozygosity (ROH) on chromosome 4.

SNP- based array, unlike array-based CGH, can identify copy-number changes as well as ROH, which indicates uniparental disomy (UPD) or identity by descent (IBD) [21]. When the ROHs exist on multiple chromosomes, they usually suggest IBD, i.e. inheritance from a common ancestor [22]. In contrast, UPD is

| Size (Mb) | N of pathogenic CNVs (%) | N of VOUS (%) | N of benign CNVs (%) |
|----------|--------------------------|---------------|----------------------|
| <0.5     | 1 (5.9)                  | 4 (26.7)      | 6 (60)               |
| 0.5-1    | 2 (11.8)                 | 5 (33.3)      | 1 (10)               |
| 1-5      | 7 (41.2)                 | 4 (26.7)      | 3 (30)               |
| 5-10     | 5 (29.4)                 | 1 (6.7)       | 0 -                  |
| >10      | 2 (11.8)                 | 1 (6.7)       | 0 -                  |
| Total    | 17 (100)                 | 15 (100)      | 10 (100)             |

Abbreviations: Mb, megabase; CNV, copy number variation; VOUS, variant of uncertain clinical significance.
suspected when the large ROH is on a single chromosome [22].
ROH may have pathogenic implications in two ways: if there are
imprinted genes within the region, or if it leads to homozygosity
for deleterious alleles involved in autosomal recessive disorders
[23]. In our case, 28 OMIM genes map to this 17.1 Mb ROH on
chromosome 4. Previous reports included chromosome 4 UPD
in a patient with mental disorder [23] and an interstitial deletion
at 4q32q34, a region that overlaps with our case, in a patient
with DD and dysmorphism [24]. However, multiple ROHs can
be detected in a normal population. Therefore, caution should
be exercised when reporting and interpreting ROH [22]. A pa-
rental study and genetic counseling should be recommended in
this instance.

3) Cri du chat syndrome
A 3-yr-old male (Table 2, Case 4) visited the psychiatric depart-
ment for speech delay. He also had esotropia in his left eye and
was diagnosed as having DD. MLPA with P245 probemix re-
vealed deletion in only one probe site on exon 3 of _TERT_ gene
(Fig. 1A), which is known to be involved in the phenotype of cri
du chat syndrome (MIM 123450). CMA showed a deletion at
5p15.33p15.31(113,576-7,183,668) (Fig. 1B), confirming the
MLPA result. A decreased signal for only one probe in MLPA ex-
periment can indicate a false-positive result owing to polymor-
phism in the probe ligation site [25]. Therefore, confirmation of
MLPA finding by another method is essential in such cases [25].
The region involved in the cri du chat syndrome is known to be
variable in size, and it can be a terminal or an interstitial deletion
[26]; so confirmative tests like CMA can be of help.

**DISCUSSION**

We conducted CMA analysis in 96 unexplained DD, MR, and
ASD patients with normal karyotype as assessed by conventional
cytogenetics. The diagnostic yield of CMA was 15.6%, which is
higher than the average rate from previous reports including
chromosomal aneuploidies (12.2%) [5]. Our finding supports
the necessity of implementing CMA as a routine diagnostic test
in the Korean population. Moreover, first-tier use of CMA for
clinical genetic evaluation of unexplained DD, MR, and ASD in
the Korean population could be beneficial for patients, consid-
ering the cost-effectiveness of CMA compared with current con-
ventional cytogenetics and MLPA or FISH test strategy [27-29].
Owing to the significantly higher diagnostic yield of CMA (CMA
15.6% vs. MLPA for the four microdeletion syndromes 2.1%),
an additional 13.5% of patients with genetic etiology can be di-
agnosed through initial CMA testing and can save much time,
cost, and effort from additional diagnostic tests.

Although we found no pathogenic CNV in patients with ASD
and ASD combined with DD/MR, the possibility of later onset of
symptoms of autistic features in these patients has to be consid-
ered, with regard to the previous findings about high frequency
of pathogenic CNVs in ASD patients [1, 30, 31].

It is known that the size of CNV is of limited importance in in-
terpretation of pathogenicity [9]. The size distribution of patho-
genic CNVs varied a lot in this study. Pathogenic CNVs greater
than 5 Mb were missed by conventional cytogenetics in six cases
(Cases 2, 3, 4, 6, 9, and 11). One patient (Case 3) had a terminal
deletion on chromosome 4 and a terminal duplication on chro-
mosome 10. Initially, the karyotype of the patient was interpreted
as normal; however, after referring to the CMA results, a reanaly-
sis of the karyotype revealed der(4)(4;10)(q35;p15). Case 11 with
Angelman syndrome had a 6 Mb-sized deletion downstream of
the centromere. Four of these six cases (Cases 2, 4, 6, and 9) in-
volved a terminal deletion. Although 5-6 Mb is usually considered
to be the detection limit of conventional G-banded karyotyping, some cases, such as chromosome abnormalities involving terminal or near-centromere regions, can be missed [11].

Among our cases, two patients (2/96, 2.1%) were diagnosed as having Phelan-McDermid syndrome (MIM 606232). These two patients had deletions in 22q13 region, involving ARSA and SHANK3 loci (Cases 7 and 15). Haploinsufficiency of the SHANK3 product is known to have a causative role in neurologic symptoms in Phelan-McDermid syndrome [32]. Deletions, translocations, or point mutations involving SHANK3 locus have been reported as pathogenic in ASD/DD [32–34]. Higher frequency of CNVs involving SHANK3 was reported in Chinese patients (1.7%), compared with 20 studies of European, American, and Australian populations (0.24%) [34]. The prevalence of imbalance involving SHANK3 in our study (2.1%) was also higher than that reported in a previous study of Caucasian population (0.24%) [34], suggesting higher frequency of Phelan-McDermid syndrome in DD/MR/ASD patients among East Asians.

The result of a parental study [5] is one of the most useful evidences of clinical significance of CNVs found in a patient. The interpretation of VOUS can be helped from the information whether it is inherited from a healthy parent or if it occurred de novo in the proband [5]. The absence of parental analysis is a limitation of our study. Although we could not validate VOUS with a parental study and only included patients with normal karyotype, the detection rate of pathogenic CNVs in our study was higher than that in previous reports [5]. Parental studies will help not only the interpretation of clinical significance of CNVs, but also the genetic counseling and evaluation of recurrence risk of the genetic abnormality in families, when CMA is available as a routine diagnostic test in future in Korea.

One major obstacle in implementing CMA as a routine diagnostic test is the current introduction system for medical technology in Korea [35]. All new diagnostic tests, including genetic tests, must go through a unified regulatory process. It is possible to apply to New Health Technology Assessment of Health Insurance Review & Assessment Service for a new medical device after getting permission from Ministry of Food and Drug Safety in Korea. Rapidly changing technology in clinical genomic testing requires a flexible system for assessing newly introduced medical procedures and health technology.

Authors’ Disclosures of Potential Conflicts of Interest

No potential conflicts of interest relevant to this article were reported.

Acknowledgments

This study was supported by a faculty research grant of Yonsei University College of Medicine for 2014 (6-2014-0145).

REFERENCES

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Washington, D.C.: American Psychiatric Association, 2013.
2. Battaglia A, Doccini V, Bernardini L, Novelli A, Loddo S, Capalbo A, et al. Confirmation of chromosomal microarray as a first-tier clinical diagnostic test for individuals with developmental delay, intellectual disability, autism spectrum disorders and dysmorphic features. Eur J Paediatr Neurol 2013;17:589-99.
3. Weiss LA, Shen Y, Korn JM, Arking DE, Miller DT, Fossdal R, et al. Association between microdeletion and microduplication at 16p11.2 and autism. N Engl J Med 2008;358:667-75.
4. Moeschler JB, Shevell M; American Academy of Pediatrics Committee on Genetics. Clinical genetic evaluation of the child with mental retardation or developmental delays. Pediatrics 2006;117:2304-16.
5. Miller DT, Adam MP, Aradhya S, Biesecker LG, Brothman AR, Carter NP, et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet 2010;86:749-64.
6. Rauch A, Hoyer J, Guth S, Zweier C, Kraus C, Becker C, et al. Diagnostic yield of various genetic approaches in patients with unexplained developmental delay or mental retardation. Am J Med Genet A 2006;140:2063-74.
7. Wagenstaller J, Spranger S, Lorenz-Depiereux B, Kazmierczak B, Nathrath M, Wahl D, et al. Copy-number variations measured by single-nucleotide-polymorphism oligonucleotide arrays in patients with mental retardation. Am J Hum Genet 2007;81:768-79.
8. Bi W, Borgan C, Pursley AN, Hixson P, Shaw CA, Bacino CA, et al. Comparison of chromosome analysis and chromosomal microarray analysis: what is the value of chromosome analysis in today’s genomic array era? Genet Med 2013;15:450-7.
9. Kearney HM, Thorland EC, Brown KK, Quintero-Rivera F, South ST. American College of Medical Genetics and standards and guidelines for interpretation and reporting of postnatal constitutional copy number variants. Genet Med 2011;13:680-5.
10. Richards S, Aziz N, Bale S, Bick D, Das S, Gastler-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17:405-23.
11. Xiang B, Zhu H, Shen Y, Miller DT, Lu K, Hu X, et al. Genome-wide oligonucleotide array comparative genomic hybridization for etiological diagnosis of mental retardation: a multicenter experience of 1499 clinical cases. J Mol Diagn 2010;12:204-12.
12. Pinto D, Marshall C, Feuk L, Scherer SW. Copy-number variation in control population cohorts. Hum Mol Genet 2007;16 Spec No. 2;R168-73.
13. Glancy M, Barnicoat A, Vjeratnam R, de Souza S, Gilmore J, Huang S, et al. Transmitted duplication of 8p23.1-8p23.2 associated with speech delay, autism and learning difficulties. Eur J Hum Genet 2009;17:37-43.

http://dx.doi.org/10.3343/alm.2015.35.5.510
14. Parisi MA, Bennett CL, Eckert ML, Dobyns WB, Gleeson JG, Shaw DW, et al. The NPHP1 gene deletion associated with juvenile nephropathies is present in a subset of individuals with Joubert syndrome. Am J Hum Genet 2004;75:82-91.

15. Adly N, Alhashem A, Ammari A, Alkuraya FS. Ciliary genes TBC1D32/60orf170 and SCLT1 are mutated in patients with ODF type IX. Hum Mutat 2014;35:36-40.

16. Nowaczyk MJ and Iorns MB. Smith-Lemli-Opitz syndrome: phenotype, natural history, and epidemiology. Am J Med Genet C Semin Med Genet 2012;160C:250-62.

17. Weaver DD, Solomon BD, Akin-Samson K, Kelley RI, Muenke M. Cyclopia (synophthalmia) in Smith-Lemli-Opitz syndrome: first reported case and consideration of mechanism. Am J Med Genet C Semin Med Genet 2010;154C:142-5.

18. Vona B, Nanda I, Neuner C, Schröder J, Kalscheuer VM, Shehata-Diel er W, et al. Terminal chromosome 4q deletion syndrome in an infant with hearing impairment and moderate syndromic features: review of literature. BMC Med Genet 2014;15:72.

19. Bernardini L, Sinibaldi L, Capalbo A, Bottilio I, Mancuso B, Torres B, et al. HDR (Hydroparathyroidism, Deafness, Renal dysplasia) syndrome associated to GATA3 gene duplication. Clin Genet 2009;76:117-9.

20. Cingoz S, Bisaard AM, Bache I, Bryndorf T, Kirchoff M, Petersen W, et al. 4q35 deletion and 10p15 duplication associated with immunodeficiency. Am J Med Genet A 2006;140:2231-5.

21. Papenhausen P, Schwartz S, Risheg H, Keitges E, Gadi I, Burnside RD, et al. UPD detection using homozygosity profiling with a SNP genotyping microarray. Am J Med Genet A 2011;155A:757-68.

22. Rehder CW, David KL, Hirsch B, Toriello HV, Wilson CM, Kearney HM. American College of Medical Genetics and Genomics: standards and guidelines for documenting suspected consanguinity as an incidental finding of genomic testing. Genet Med 2013;15:150-2.

23. Middleton FA, Trauzzi MG, Shrimpton AE, Gentile KL, Morley CP, Me deiros H, et al. Complete maternal uniparental isodisomy of chromosome 4 in a subject with major depressive disorder detected by high density SNP genotyping arrays. Am J Med Genet B Neuropsychiatr Genet 2006;141B:28-32.

24. Ramanathan S, Woodroffe A, Flodman PL, Mays LZ, Hanouni M, Modahl CB, et al. A case of autism with an interstitial deletion on 4q leading to hemizygosity for genes encoding for glutamine and glycine neurotransmitter receptor sub-units (AMPA 2, GLRA3, GLRB) and neuropeptide receptors NPY1R, NPY5R. BMC Med Genet 2004;5:10.

25. Taylor CF, Charlton RS, Burn J, Sheridan E, Taylor GR. Genomic deletions in MSH2 or MLH1 are a frequent cause of hereditary non-polypoid colorectal cancer: identification of novel and recurrent deletions by MLPA. Hum Mutat 2003;22:428-33.

26. Zhang X, Snijders A, Segrevas R, Zhang X, Niebuhr A, Albertson D, et al. High-resolution mapping of genotype-phenotype relationships in cri du chat syndrome using array comparative genomic hybridization. Am J Hum Genet 2005;76:312-26.

27. Wordsworth S, Buchanan J, Regan R, Davison V, Smith K, Dyer S, et al. Diagnosing idiopathic learning disability: a cost-effectiveness analysis of microarray technology in the National Health Service of the United Kingdom. Genomic Med 2007;1:35-45.

28. Trakadas Y and Shevell M. Microarray as a first genetic test in global developmental delay: a cost-effectiveness analysis. Dev Med Child Neurol 2011;53:994-9.

29. Coulter ME, Miller DT, Harris DJ, Hawley P, Picker J, Roberts AE, et al. Chromosomal microarray testing influences medical management. Genet Med 2011;13:770-6.

30. Roberts JL, Hovanes K, Dasouki M, Manzardo AM, Butler MG. Chromosomal microarray analysis of consecutive individuals with autism spectrum disorders or learning disability presenting for genetic services. Gene 2014;535:70-8.

31. Nicholl J, Waters W, Mulley JC, Suwalski S, Brown S, Hull Y, et al. Cognitive deficit and autism spectrum disorders: prospective diagnosis by array CGH. Pathology 2014;46:41-5.

32. Bonaglia MC, Giorda R, Beri S, De Agostini C, Novara F, Fichera M, et al. Molecular mechanisms generating and stabilizing terminal 22q13 deletions in 44 subjects with Phelan/McDermid syndrome. PLoS Genet 2011;7:e1002173.

33. Bonaglia MC, Giorda R, Borgatti R, Felisari G, Gagliardi C, Selicorni A, et al. Disruption of the ProSAP2 gene in a t(12;22)(q24.1;q13.3) is associated with the 22q13.3 deletion syndrome. Am J Hum Genet 2001;69:261-8.

34. Gong X, Jiang YW, Zhang X, An Y, Zhang J, Wu Y, et al. High proportion of 22q13 deletions and SHANK3 mutations in Chinese patients with intellectual disability. PLoS One 2012;7:e34739.

35. Lee KA. The genetic testing system- Pending issues and future extensions. Medical Review 2014;11:22-8. http://mdzone.co.kr/news/view.php?id=13923 (Updated on April 2014).

36. Thevenon J, Callier P, Poquet H, Bache I, Menten B, Malan V, et al. 3q27.3 microdeletion syndrome: a recognisable clinical entity associating dysmorphic features, marfanoid habitus, intellectual disability and psychosis with mood disorder. J Med Genet 2014;51:21-7.

37. Pehlivan T, Pober BR, Brueckner M, Garrett R, Slaugh R, Van Rheeden N, et al. GATA4 haploinsufficiency in patients with interstitial deletion of chromosome region 8p23.1 and congenital heart disease. Am J Hum Genet 2001;69:261-8.

38. Coulter ME, Miller DT, Harris DJ, Hawley P, Picker J, Roberts AE, et al. Chromosomal microarray testing influences medical management. Genet Med 2011;13:770-6.

39. DeScipio C, Conlin L, Rosenfeld J, Tepperberg J, Pasion R, Patel A, et al. Disruption of the ProSAP2 gene in a t(12;22)(q24.1;q13.3) is associated with the 22q13.3 deletion syndrome. Am J Hum Genet 2001;69:261-8.

40. Ullmann R, Turner G, Kirchhoff M, Chen W, Tonge B, Rosenberg C, et al. Autism spectrum disorders or learning disability presenting for genetic services. J Med Genet 2014;51:21-7.